CYP8B1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 16 μg, Lane 1-2: Mouse heart tissue, Human hepatocellular carcinoma 2 tissue lysates , Primary antibody: P06898(CYP8B1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06898(CYP8B1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P06898(CYP8B1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The CYP8B1 antibody is a crucial tool for studying the enzyme cytochrome P450 family 8 subfamily B member 1 (CYP8B1), which plays a pivotal role in bile acid biosynthesis. CYP8B1 catalyzes the synthesis of cholic acid by converting 7α-hydroxy-4-cholesten-3-one into 7α,12α-dihydroxy-4-cholesten-3-one, a key step in the classical pathway of bile acid production. This enzyme regulates the balance between cholic acid and chenodeoxycholic acid, directly influencing cholesterol homeostasis, lipid absorption, and metabolic signaling. Dysregulation of CYP8B1 has been linked to metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD).

The CYP8B1 antibody enables researchers to detect and quantify CYP8B1 protein expression in tissues such as the liver and intestine, often using techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). It is particularly valuable for investigating CYP8B1's tissue-specific expression, regulatory mechanisms (e.g., under control of SREBP or FXR pathways), and alterations in disease models. High-quality antibodies are validated for specificity, ensuring minimal cross-reactivity with other cytochrome P450 enzymes.

Research utilizing CYP8B1 antibodies has advanced understanding of its therapeutic potential. Inhibiting CYP8B1 may reduce cholic acid levels, thereby modulating bile acid composition to improve metabolic parameters—a promising avenue for treating metabolic syndrome. This antibody remains essential for exploring CYP8B1's role in lipid metabolism and its implications in drug development.